A carregar...
How I treat relapsed and/or refractory multiple myeloma
The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes. These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylas...
Na minha lista:
| Publicado no: | Hematol Rep |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
PAGEPress Publications, Pavia, Italy
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7520845/ https://ncbi.nlm.nih.gov/pubmed/33042504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/hr.2020.8955 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|